Methotrexate (MTX) is a prominent treatment for patients with Rheumatoid Arthritis (RA) but its effectiveness may be impacted by bothersome side effects and lack of tolerability. This cross-sectional study by Curtis et al. surveyed RA patients who were members of CreakyJoints who participated in subcutaneous or oral MTX treatment in the last 12 months. 382 patients were surveyed, and they reported side effects such as diarrhea, fatigue, malaise, and hair loss. Higher doses of MTX were associated with a greater likelihood of more side effects.
Research for patients, by patients.
A Creakyjoints initiative.
PatientSpot registry infrastructure was funded through a Patient-Centered Outcomes Research Institute Award (PCORI Contract Number PPRN-1306-04811). PatientSpot (formerly known as Arthritis Power) was jointly developed by the nonprofit Global Healthy Living Foundation (GHLF), its associated CreakyJoints arthritis patient community, and rheumatology researchers at the University of Alabama at Birmingham (UAB). We reserve the right to change and add sponsors and partner organizations and we also reserve the right to change placement of text on the page. Created by CreakyJoints® patient community in collaboration with patient advocates at Global Healthy Living Foundation (GHLF) and researchers at the University of Alabama at Birmingham (UAB), Arthritis Power (now PatientSpot)’s past participation in PCORnet®, the National Patient-Centered Clinical Research Network, was supported through multiyear, multimillion-dollar Patient-Centered Outcomes Research Institute funding awards [PPRN-1306-04811]. Global Healthy Living Foundation (GHLF), the parent organization of PatientSpot, receives grants, sponsorships and contracts from pharmaceutical manufacturers and private foundations. A full list of GHLF funders is publicly available here: https://www.ghlf.org/our-partners.
POWERED BY
© Copyright 2024 PatientSpot